Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, TREND1, lakingsphan0427 , Phaeton, $Pistol Pete$
Search This Board: 
Last Post: 1/21/2018 8:08:31 AM - Followers: 395 - Board type: Free - Posts Today: 2


Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.        

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Alfred E. Mann, Founder (Deceased)

Alfred E. Mann had been one of MNKD's directors since April 1999, Chairman of the Board since December 2001 and  Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: Current Report Filing (8-k) 01/19/2018 06:53:47 AM
MNKD News: MannKind Corporation to Present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference 01/16/2018 09:00:00 AM
MNKD News: Statement of Changes in Beneficial Ownership (4) 12/20/2017 04:55:10 PM
MNKD News: Current Report Filing (8-k) 12/13/2017 04:33:36 PM
MNKD News: Confidential Treatment Order (ct Order) 12/06/2017 04:12:18 PM
#23743  Sticky Note $MNKD MannKind and Biomm Enter Into Distribution Agreement $Pistol Pete$ 06/01/17 01:49:35 AM
#23541  Sticky Note Buffalo teacher a key advocate in breakthrough diabetes drug Phaeton 05/19/17 12:07:29 PM
#27101   Great! But why this product is not exploding Unoqualunque 01/21/18 08:08:31 AM
#27100 WHS 01/21/18 05:00:53 AM
#27099   Big issue, if scripts are not rising cash Unoqualunque 01/20/18 11:54:05 AM
#27098   Thanks for sharing $Pistol Pete$ 01/20/18 11:36:22 AM
#27097   MNKD Update on Seeking Alpha conix 01/20/18 10:39:43 AM
#27096 WHS 01/19/18 11:11:16 PM
#27095   Whoa! Those are giant biotech companies compare to lakingsphan0427 01/19/18 12:41:33 PM
#27094   MNKD break of 2.60 BluSkies 01/19/18 11:41:17 AM
#27093   Thanks for the info! Go4itbigtime 01/17/18 04:32:51 PM
#27092   5 Big Biotech Stocks To Buy In 2018 Phaeton 01/17/18 04:10:49 PM
#27091   MannKind and the LA Kings Diabetes awareness night. Phaeton 01/17/18 02:21:37 PM
#27090   $MNKD 15' Chart $Pistol Pete$ 01/17/18 10:06:23 AM
#27089   You need that kind of R@R after a Profit 01/12/18 09:42:05 PM
#27088   Holiday weekend he probably went from the JPM Phaeton 01/12/18 08:31:37 PM
#27087   In MNKD's case, any biotech deal that would nobodysbusiness 01/12/18 05:41:55 PM
#27086   yeah Profit 01/12/18 05:24:51 PM
#27085   Biotech deals can take a really long time SidVicious 01/12/18 05:21:46 PM
#27084   Cruel joke either way. BluSkies 01/12/18 04:56:42 PM
#27083   Could they really still be negotiating this or Profit 01/12/18 04:51:25 PM
#27082   Odds are not in favor of news that SidVicious 01/12/18 12:25:05 PM
#27081   Time is running out hopefully we hear soon. BluSkies 01/11/18 12:09:10 PM
#27080   With the right news a short squeeze could Profit 01/11/18 10:17:41 AM
#27079   I think potential parter was waiting to see BluSkies 01/11/18 09:32:33 AM
#27078   MNKD release some good news & short squeeze BluSkies 01/11/18 09:22:26 AM
#27077   I've seen better looking sharts than that chart. SidVicious 01/10/18 09:58:20 PM
#27076   Short interest up by another 850,000 as of Profit 01/10/18 07:35:46 PM
#27075   This needs to seal up Deerfield by the BluSkies 01/10/18 01:15:50 PM
#27074   $MNKD Daily and Weekly Charts http://www.stock $Pistol Pete$ 01/10/18 12:49:32 PM
#27073   $MNKD 15' Chart $Pistol Pete$ 01/10/18 12:19:26 PM
#27072   This looks ready to soar imo BluSkies 01/10/18 12:17:03 PM
#27071   WHY would drug companies change the delivery system BluSkies 01/10/18 08:51:01 AM
#27070   Blu, Technosphere is several decades old and Mannkind SidVicious 01/10/18 08:27:56 AM
#27069   "nate's Notes"? Are you serious? That guy has nobodysbusiness 01/10/18 08:19:39 AM
#27067   Pretty sure these shorts are hedged and fully Profit 01/09/18 11:18:42 PM
#27066   Hopefully they're working on inking a deal soon BluSkies 01/09/18 11:01:11 PM
#27065   If he is at the conference he is Profit 01/09/18 10:18:07 PM
#27064   CEO very active on twitter today. I wonder BluSkies 01/09/18 09:29:32 PM
#27063   Along with Afrezza, the company also owns the BluSkies 01/09/18 09:28:37 PM
#27062   No short squeeze will happen and don't hold SidVicious 01/09/18 09:27:17 PM
#27060   Short squeeze soon after 2.60 break? BluSkies 01/09/18 02:57:26 PM
#27059   I'll take fundamentals over technicals....need + news Go4itbigtime 01/09/18 02:53:55 PM
#27058   Nice bid at 2.55 holding up support on BluSkies 01/09/18 02:14:35 PM
#27057   Haha....I always follow the chart my Friend $Pistol Pete$ 01/09/18 12:33:04 PM
#27056   Glad someone else saw what I saw lol BluSkies 01/09/18 12:25:07 PM
#27055   Getting close.. news would be nice during the BluSkies 01/09/18 12:12:40 PM
#27054   Agreed $Pistol Pete$ 01/09/18 10:18:03 AM
#27053   Technical breakout on watch today and this week. BluSkies 01/09/18 08:41:39 AM
#27052 BluSkies 01/09/18 08:38:06 AM
#27051   $MNKD $Pistol Pete$ 01/09/18 01:05:58 AM
#27050   Hoping we get a push up by Jan BluSkies 01/08/18 12:33:09 PM